Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab (CSL312) prophylaxis in hereditary angioedema
jRCT2031210056Completed
- Sponsor
- CSL Limited
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in hereditary angioedema (HAE) comparing Garadacimab arm with Placebo arm (2 arms). Primary endpoint: Time-normalized number of HAE attacks during treatment period. Started Aug 2021; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031210056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210056.